Article Information
History
- August 30, 2022.
Article Versions
- You are currently viewing Version 1 of this article (August 30, 2022 - 13:18).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Chia En Lien1,2,
- Ming-Che Liu3,
- Ning-Chi Wang4,
- Luke Tzu-Chi Liu1,
- Chung-Chin Wu1,
- Wei-Hsuan Tang1,
- Wei-Cheng Lian1,
- Kuan-Ying A. Huang5,6,7,* and
- Charles Chen1,8,*
- 1Medigen Vaccine Biologics Corporation, Taipei, Taiwan
- 2Institute of Public Health, National Yang-Ming Chiao Tung University, Taipei City, Taiwan
- 3Clinical Research Centre, Taipei Medical University Hospital Taipei, Taiwan
- 4Tri-Service General Hospital, Taipei, Taiwan
- 5Research Center for Emerging Viral Infections, College of Medicine, Chang Gung University, Taoyuan, Taiwan
- 6Genomics Research Center, Academia Sinica, Taipei, Taiwan
- 7Division of Pediatric Infectious Diseases, Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan
- 8College of Science and Technology, Temple University, Philadelphia, PA 19122, USA
- ↵*Co-Corresponding authors: Kuan-Ying A. Huang: arthur1726{at}cgmh.org.tw; Charles Chen: charles{at}medigenvac.com
Posted August 30, 2022.
A Phase I, Prospective, Randomized, Open-labeled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Booster Dose with MVC-COV1901 or MVC-COV1901(Beta) SARS-CoV-2 Vaccine in Adults
